Future investigations in this model will elucidate whether MCP1 inhibitors can ameliorate neuroinflammation and, potentially, hydrocephalus progression or functional outcomes, as shown in other disease models such as experimental autoimmune encephalomyelitis (Ge et al., 2012) or ethanol-induced neurodegeneration (Zhang et al., 2018). Here, CCL2 is linked to experimental autoimmune encephalomyelitis.